Combined Seton Placement, Infliximab Infusion, and Maintenance Immunosuppressives Improve Healing Rate in Fistulizing Anorectal Crohn’s Disease
Tóm tắt
PURPOSE: Infliximab (anti-TNF α) has been used for the treatment of fistulizing Crohn’s disease with variable efficacy. The aim of this study was to evaluate the efficacy of infliximab combined with selective seton drainage in the healing of fistulizing anorectal Crohn’s disease.
METHODS: This was a retrospective chart review of all patients with fistulizing Crohn’s disease treated with infliximab between March 2000 and February 2002.
RESULTS: Twenty-nine patients (12 male; mean age, 31 years) received a mean of 3 (range, 1–5) doses of infliximab 5 mg/kg. Twenty-one patients had perianal fistulas; eight had rectovaginal fistulas, four with combined rectovaginal/perianal fistula. Fourteen of 21 patients (67 percent) with perianal fistula had a complete response (mean follow-up, 9 months), 4 of the 14 relapsed (mean, 6 months), but all had a complete response to retreatment (mean, 9 months). A partial response occurred in four patients (19 percent), defined by decreased drainage (2 patients) or infliximab dependence (2 patients) requiring repeated dosing every six to eight weeks. Three patients (14 percent) had no response. Seton drainage was used before infusion in 13 perianal patients for perianal infection and 17 were treated with maintenance azathioprine or methotrexate. Of eight patients with rectovaginal fistula, complete response occurred in one, partial response in five, and no response in two. Two partial responders became infliximab dependent. A complete response was observed in one patient with isolated rectovaginal fistula, a partial response in five. No patient with a combined rectovaginal/perianal fistula had a complete response. Five rectovaginal fistula patients were taking maintenance immunosuppressive agents and two had seton drainage before infusion.
CONCLUSIONS: Selective seton placement combined with infliximab infusion and maintenance immunosuppressives resulted in complete healing in 67 percent of Crohn’s patients with perianal fistula and partial healing in 19 percent. Relapse was successfully treated with repeat infusion. Concomitant rectovaginal fistula was a poor prognostic indicator for successful infliximab therapy.
Tài liệu tham khảo
DA Schwartz EV Loftus WJ Tremaine et al. (2002) ArticleTitleThe natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota Gastroenterology 122 875–880
DH Present P Rutgeerts S Targan et al. (1999) ArticleTitleInfliximab for the treatment of fistulas in patients with Crohn’s disease N Engl J Med 340 1398–1405
B Ursing C Kamme (1975) ArticleTitleMetronidazole for Crohn’s disease Lancet 1 775–777
LH Bernstein MS Frank LJ Brandt SJ Boley (1980) ArticleTitleHealing of perineal Crohn’s disease with Metronidazole Gastroenterology 79 357–365
LJ Brandt LH Bernstein SJ Boley MS Frank (1982) ArticleTitleMetronidazole therapy for perineal Crohn’s disease Gastroenterology 83 383–387
J Jakobovits MM Schuster (1984) ArticleTitleMetronidazole therapy for Crohn’s disease and associated fistulae Am J Gastroenterol 79 533–540
J Rhodes D Bainton P Beck H Campbell (1971) ArticleTitleControlled trial of azathioprine in Crohn’s disease Lancet. 2 1273–1276
BI Korelitz DH Present (1985) ArticleTitleFavorable effect of 6-mercaptopurine on fistulae of Crohn’s disease Dig Dis Sci 30 58–64
J Markowitz J Rosa K Grancher H Aiges F Daum (1990) ArticleTitleLong-term 6-mercaptopurine treatment in adolescents with Crohn’s disease Gastroenterology 99 1347–1351
DH Present BI Korelitz N Wisch JL Glass DB Sachar BS Pasternack (1980) ArticleTitleTreatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study N Engl J Med 302 981–987
DH Present S Lichtiger (1994) ArticleTitleEfficacy of Cycolsporine in treatment of fistula of Crohn’s disease Dig Dis Sci 39 374–380
SB Hanauer MB Smith (1993) ArticleTitleRapid closure of Crohn’s disease fistulas with continuous intravenous Cyclosporine A Am J Gastroenterol 88 646–649
PW Lowry AL Weaver WJ Tremaine WJ Sandborn (1999) ArticleTitleCombination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment refractory Crohn’s disease perianal fistulae Inflamm Bowel Dis 5 239–245
I Bayer PH Gordon (1994) ArticleTitleSelected operative management of fistula-in-ano in Crohn’s disease Dis Colon Rectum 37 760–765
RD Cohen JF Tsang SB Hanauer (2000) ArticleTitleInfliximab in Crohn’s disease Am J Gastroenterol 95 3469–3477
C Sample RJ Bailey D Todoruk et al. (2002) ArticleTitleClinical experience with infliximab for Crohn’s disease Can J Gastroenterol 16 165–170
ID Arnott D McDonald A Williams S Ghosh (2001) ArticleTitleClinical use of Infliximab in Crohn’s disease Aliment Pharmacol Ther 15 1639–1646
E Ricart R Panaccione EV Loftus WJ Tremaine WJ Sandborn (2001) ArticleTitleInfliximab for Crohn’s disease in clinical practice at the Mayo Clinic Am J Gastroenterol 96 722–729
RJ Farrell SA Shah PJ Lodhavia et al. (2000) ArticleTitleClinical experience with infliximab therapy in 100 patients with Crohn’s disease Am J Gastroenterol 95 3490–3497
AA van Bodegraven CE Sloots RJ Felt-Bersma SG Meuwissen (2002) ArticleTitleEndosonographic evidence of persistence of Crohn’s disease-associated fistulas after infliximab treatment, irrespective of clinical response Dis Colon Rectum 45 39–45
TF Schaible (2000) ArticleTitleLong term safety of infliximab Can J Gastroenterol 14 29–32
A Ky N Sohn MA Weinstein BI Korelitz (1998) ArticleTitleCarcinoma arising in anorectal fistulas of Crohn’s disease Dis Colon Rectum 41 992–996